Guardant Health Inc (GH)

Guardant Health Inc (GH) 最新ニュース

Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics

Zacks Investment Research

Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates

Zacks Investment Research

Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect

Zacks Investment Research

Curious about Guardant Health (GH) Q1 Performance? Explore Wall Street Estimates for Key Metrics

Zacks Investment Research

Key Takeaways From Guardant Health Analyst Ratings

Benzinga

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks Investment Research

Analyst Expectations For Guardant Health's Future

Benzinga

REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday

Benzinga

Insiders Buying Advance Auto Parts And 2 Other Stocks

Benzinga

Cancer Test Focused Guardant Health Stock Falls On FDA AdCom Update For Colorectal Test

Benzinga

4 Analysts Have This To Say About Guardant Health

Benzinga

Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet

Zacks Investment Research

NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates

Zacks Investment Research

Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Down -12.91% in 4 Weeks, Here's Why Guardant Health (GH) Looks Ripe for a Turnaround

Zacks Investment Research

Guardant Health (GH) Loses -13.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research

Decoding 4 Analyst Evaluations For Guardant Health

Benzinga

Bull of the Day: NeoGenomics (NEO)

Zacks Investment Research

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024

The Motley Fool

Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA's Panel Surprise Advisory Possibility: Analyst

Benzinga

S&P 500, Nasdaq Set For Weaker Open As 'FOMO' Rally Cools: Analyst Says Only 'Black Swan Could Upset Santa's Sleigh' Now

Benzinga

What 7 Analyst Ratings Have To Say About Guardant Health

Benzinga

Jim Cramer: Buy This Financial Stock, 'It's Up Substantially From Where It Was In The Spring'

Benzinga

7 Analysts Have This to Say About Guardant Health

Benzinga